BerGenBio AS today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class AXL inhibitor, which will target drug resistant and metastatic cancers. BTO has helped the researchers in negotiating license agreements, patenting, raising funding from several sources of capital, and provided other business development tasks.
BerGenBio AS is an emerging oncology-based biopharmaceutical company located in Bergen, and was established in 2007 together with the Univeristy of Bergen, UNIResearch and BTO. BGB324 is the first of a planned pipeline of oncology therapeutics planned for clinical development through to phase II in partnership with industry leaders.
Complete pressrelease here (no longer available).